Spending on glucagon-like peptide-1 receptor agonists among US adults
About The Study: Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased substantially, spending declined for others. This study estimated that more than $71 billion was spent on GLP-1 RAs and more than $50 billion on a product based on either semaglutide or tirzepatide molecules.
Corresponding Author: To contact the corresponding author, Stavros Tsipas, MA, email stavros.tsipas@ama-assn.org.
To ...















